MentionFox
Home › funding signals › BigHat Biosciences, Inc.
Form D · on the record

BigHat Biosciences — $75.14M Form D filing, October 2026

BigHat Biosciences, Inc. filed a Form D with the Securities and Exchange Commission on 2026-10-26.

BigHat Biosciences, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 26, 2026. The filing reports $75.14M sold. Its industry group is Biotechnology. It names Peyton Greenside (Executive Officer, Director), Vineeta Agarwala (Director), Robert Chess (Director) (SEC Form D, October 26, 2026).

5 more Biotechnology raises in California, October 2026 ↓

Sell to companies like BigHat Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

Run the free check on BigHat Biosciences, Inc. →

BigHat Biosciences, Inc.

New Form D on file · 2026-10-26 · the record

$75.14M
raise on the record
D
filing
29
investors in
CALIFORNIA
based
Open the record →

What the record says

FilingForm D
Filed2026-10-26
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
BasedSAN MATEO, CALIFORNIA
CIK1797256
Accession0001231919-26-001499

Pitching, partnering or investing alongside them? See who really runs and owns BigHat Biosciences, Inc.

Watch BigHat Biosciences, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind BigHat Biosciences, Inc., from the filings we hold.

More raises like this

Biotechnology raises by companies based in California, filed in October 2026, largest first.

What do you want to do with BigHat Biosciences, Inc.?

Get the full cited report on BigHat Biosciences, Inc.

What the filing shows about BigHat Biosciences, Inc.

  • 29 investors had already put money in when it filed.
  • The filing names 5 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on BigHat Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

What the filing says

  • Offered: $79,999,947. Sold: $75,141,086. Left to sell: $4,858,861. (filing)
  • Investors: 29 had already invested. (filing)
  • Date of first sale: July 17, 2026. (filing)
  • Types of securities: Equity. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)
  • On the amounts offered and sold: the filing adds “Series C Preferred Stock and the Common Stock issuable upon conversion thereof.” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on BigHat Biosciences, Inc. See pricing

Filing history · 3 filings on this registrant
Form D · 2022-10-03 · $80MForm D/A, amended · 2025-04-28 · $124.11MForm D · 2026-10-26 · $75.14M · this page 2022-10-03 2026-10-26

A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.

Biotechnology · by week
This raise, $75.14M, filed week of Oct 26

Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $75.14M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on BigHat Biosciences, Inc.?

What the filing shows about BigHat Biosciences, Inc.

  • 29 investors had already put money in when it filed.
  • The filing names 5 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on BigHat Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on BigHat Biosciences, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind BigHat Biosciences, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

Follow this companyRSS

Tools for this story

Each opens in a new tab, filled in for BigHat Biosciences, Inc.. With no account yet, you sign up free and land on the result.

Share this page

Just raised? Share it.

BigHat Biosciences, Inc.: Raised $75.14M, Form D filed 2026-10-26

Cite this page

Permanent URL: https://mentionfox.com/funding/bighat-biosciences-inc-form-d-001499
Last updated 2026-10-27
Primary record: SEC filing 1 · SEC filing 2
BigHat Biosciences raised $75.14M — SEC Form D filing, October 2026. MentionFox, 2026-10-27. https://mentionfox.com/funding/bighat-biosciences-inc-form-d-001499